Profil Terapi dan Efek Samping Anti Tuberkulosis pada Pasien AIDS Rawat Inap
Abstract
AIDS is a global problem, including in Indonesia. AIDS patients are easy to get pulmonary tuberculosis. These patients will receive polypharmacy which require special attention to ensure patient safety. The objective of this study is to examine the usage patterns of anti-tuberculosis therapy in AIDS patients related to types, route, dose, and see whether there are any side effects during anti-tuberculosis use. This was observational and retrospective study using patient medical record, conducted at dr. Saiful Anwar hospital, Malang in the period of April-Mei 2016. Based on medical record of 36 AIDS patients with pulmonary TB, 22 patients (61%) were in the intensive phase of treatment anti-tuberculosis cate–gory I, 8 patients (22%) in the treatment of the intensive phase of category II, 2 patients (6%) in the continuation phase category I, 1 patient (3%) was in the intensive phase of category I then get a special conditions regimen of anti-tuberculosis therapy, 1 patient (3%) was in the intensive phase category II but underwent a change to the intensive phase of MDR-TB, and other 1 patient (3%) was get the intensive phase of special conditions. Drug related problems that identified were rash (6%), Steven Johnson syndrome (3%), drug induced hepatitis due to anti-tuberculosis (22%), and jaundice without other cause (3%).
Downloads
Articles published in MPI are licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA) license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and MPI, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to MPI to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
By publishing in MPI, authors grant any third party the right to use their article to the extent provided by the CC BY-SA license.